-
Archives of virology · Mar 2021
Randomized Controlled Trial Multicenter StudyEfficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
- Hany M Dabbous, Sherief Abd-Elsalam, Manal H El-Sayed, Ahmed F Sherief, Fatma F S Ebeid, El GhafarMohamed Samir AbdMSADepartment of Anesthesia, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Shaimaa Soliman, Mohamed Elbahnasawy, Rehab Badawi, and Mohamed Awad Tageldin.
- Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Arch. Virol. 2021 Mar 1; 166 (3): 949-954.
AbstractNo specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:

- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.